var data={"title":"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/360810?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215528\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Kinrix;</li>\n      <li>Quadracel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14790063\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Adacel-Polio;</li>\n      <li>Boostrix-Polio;</li>\n      <li>Infanrix-IPV;</li>\n      <li>Quadracel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215688\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial);</li>\n      <li>\n        Vaccine, Inactivated (Viral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14790522\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster immunization:</b> Adacel-Polio, Boostrix-Polio [Canadian products]: IM: 0.5 mL as a single dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215824\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immunization: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i> Kinrix, Quadracel: IM: Children 4 to 6 years: 0.5 mL as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adacel-Polio: IM: Children &ge;4 years and Adolescents: Refer to adult dosing for booster dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Boostrix-Polio: IM: Children &ge;4 years, and Adolescents: Refer to adult dosing for booster dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infanrix-IPV: Children 15 months to 6 years: IM: 0.5 mL as initial booster dose at 15 to 18 months of age and 0.5 mL as second booster dose between 4 to 6 years (may be administered with monovalent <i>H. Influenzae</i> type b vaccine). If primary immunization is delayed, same booster interval can be used prior to seventh birthday.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Quadracel: IM: Infants &ge;2 months and Children to 6 years: 0.5 mL administer as a 4 dose primary series, usually given at 2, 4, 6, and 18 months of age; followed by a booster dose at 4 to 6 years of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15796187\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15796188\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215828\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kinrix: Diphtheria toxoid 25 Lf, tetanus toxoid 10 Lf, acellular pertussis antigens [inactivated pertussis toxin 25 mcg, filamentous hemagglutinin 25 mcg, pertactin 8 mcg], type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate, polymyxin B, polysorbate 80; may contain natural rubber/natural latex in prefilled syringe]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Quadracel: Diphtheria toxoid 15 Lf, tetanus toxoid 5 Lf, acellular pertussis antigens [detoxified pertussis toxin 20 mcg, filamentous hemagglutinin 20 mcg, pertactin 3 mcg, fimbriae (types 2 and 3) 5 mcg], type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate, polymyxin B, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215686\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14790523\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adacel-Polio: Diphtheria toxoid 2 Lf, tetanus toxoid 5 Lf, acellular pertussis antigens [inactivated pertussis toxoid 2.5 mcg, filamentous hemagglutinin 5 mcg, pertactin 3 mcg, types 2 and 3 fimbriae 5 mcg], type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate, polymyxin B, polysorbate 80, streptomycin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Boostrix-Polio: Diphtheria toxoid 2.5 Lf, tetanus toxoid 5 Lf, acellular pertussis antigens [inactivated pertussis toxoid 8 mcg, filamentous hemagglutinin 8 mcg, pertactin 2.5 mcg], type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate, polymyxin B]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infanrix-IPV: Diphtheria toxoid 25 Lf, tetanus toxoid 10 Lf, acellular pertussis antigens [inactivated pertussis toxoid 25 mcg, filamentous hemagglutinin 25 mcg, pertactin 8 mcg], type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate, polymyxin B]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Quadracel: Diphtheria toxoid 15 Lf, tetanus toxoid 5 Lf, acellular pertussis antigens [detoxified pertussis toxin 20 mcg, filamentous hemagglutinin 20 mcg, pertactin 3 mcg, fimbriae (types 2 and 3) 5 mcg], type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate, polymyxin B, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46885852\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the US, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/dtap.html&amp;token=AAHYoDAb5A/YSr8VQiRYJsJa+xtSDgw+x9go1noRHegLn8TcWE84hJbdbbfdAqbiCOgxMY984FLBv0YiMFNR1w==&amp;TOPIC_ID=8974\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/dtap.html</a> and <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/ipv.html&amp;token=Jo+TJVXtdtuhdib4J4tH0wIdFfAoQY6fCoIuVJr+FoXRX/80yLOyozFsfsL3+Mw3XHD7ANvZUg1OBus0VA9g9w==&amp;TOPIC_ID=8974\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/ipv.html</a> .</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215825\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: For IM use only, preferably in the deltoid; Adacel-Polio [Canadian product] label recommends avoiding administration into the buttocks. Quadracel (Canadian labeling) recommends administration into the anterolateral thigh for infants &lt;1 year. Infanrix-IPV [Canadian product] label recommends administration into the anterolateral thigh in young children (ie, 15 to 18 months of age). Do not administer intradermally, IV, or SubQ. Shake well prior to use; do not use unless a homogeneous, turbid, white suspension forms. Discard if the suspension is discolored or if there are cracks in the vial or syringe. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215690\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diphtheria, tetanus, pertussis, and poliovirus disease prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kinrix: Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and as the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with Infanrix (DTaP) and/or Pediarix (DTaP-hepatitis B-IPV) for the first 3 doses and Infanrix (DTaP) for the fourth dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quadracel:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling</i>: Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and as the fourth or fifth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been 4 doses of Pentacel (DTaP-IPV/Haemophilus b conjugate [tetanus toxoid conjugate] vaccine) and/or Daptacel (DTaP).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling</i>: Active primary immunization against diphtheria, tetanus, pertussis, and poliomyelitis for infants and children 6 months through 6 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adacel-Polio [Canadian product]: Active booster immunization against diphtheria, tetanus, pertussis, and poliomyelitis in patients 4 years and older; alternative to fifth dose of DTaP-IPV in patients 4 to 6 years of age; may be used for wound management when a tetanus toxoid-containing vaccine is needed for wound management [refer to current National Advisory Committee on Immunization (NACI) guidelines]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boostrix Polio [Canadian product]: Active booster immunization against diphtheria, tetanus, pertussis, and poliomyelitis in patients 4 years and older; may be used for wound management when a tetanus toxoid-containing vaccine is needed for wound management [refer to current National Advisory Committee on Immunization (NACI) guidelines]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infanrix-IPV [Canadian product]: Active booster immunization against diphtheria, tetanus, pertussis, and poliomyelitis in children &ge;15 months through 6 years of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14790062\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Adacel (trade name for Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine) should not be confused with Adacel-Polio (trade name for Diphtheria and Tetanus Toxoids, Acellular Pertussis, and Poliovirus Vaccine in Canada)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Boostrix (trade name for Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine) should not be confused with Boostrix-Polio (trade name for Diphtheria and Tetanus Toxoids, Acellular Pertussis, and Poliovirus Vaccine in Canada)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Infanrix (trade name for Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine) should not be confused with Infanrix-IPV (trade name for Diphtheria and Tetanus Toxoids, Acellular Pertussis, and Poliovirus Vaccine in Canada)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">DTaP-IPV (diphtheria and tetanus toxoids, acellular pertussis and poliovirus [inactivated] vaccine) may be confused with DTaP-IPV/Hib (diphtheria and tetanus toxoids, acellular pertussis, poliovirus [inactivated], and <i>Haemophilus influenzae</i> type b conjugate vaccine) and DTaP-HepB-IPV (diphtheria and tetanus toxoids, acellular pertussis, hepatitis B, and poliovirus [inactivated] vaccine)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Repevax [Multiple International Markets] may be confused with Revaxis brand name for diphtheria, tetanus, and poliomyelitis vaccine [Multiple International Markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215807\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>All serious adverse reactions must be reported to the US Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at <a target=\"_blank\" href=\"https://vaers.hhs.gov/esub/index&amp;token=8m3rK0tzv73hmwLVujPJP0lWL2FxLWQizZTxo5kD83IMEaCGiDnUFaD+0my2cUJQ&amp;TOPIC_ID=8974\" target=\"_blank\">https://vaers.hhs.gov/esub/index</a>.</b> In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adverse events reported within 4 to 7 days of vaccination:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Swelling of injected limb (arm circumference increase: 36% to 68%), swelling of injected limb (extensive, 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Malaise (35%), drowsiness (19%), headache (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Decreased appetite (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site: Pain at injection site (57% to 77%), erythema at injection site (37% to 59%), swelling (26% to 40%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (54%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (6% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abscess at injection site, anaphylaxis, cerebrovascular accident, convulsions, cyanosis, dehydration, febrile seizures, gastroenteritis, hypernatremia, hypersensitivity reaction, hypotonia, hypotonic/hyporesponsive episode, inflammation at injection site, injection site cellulitis, lethargy, pallor, pruritus, residual mass at injection site, screaming, skin vesicle (injection site), sterile abscess at injection site, syncope</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215695\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe allergic reaction (eg, anaphylaxis) after a previous dose of any diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, or inactivated poliovirus vaccine, or to any component of the vaccine, including neomycin and polymyxin B; encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause; progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boostrix Polio [Canadian product]: Additional contraindications: History of transient thrombocytopenia following an earlier immunization against diphtheria and/or tetanus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215696\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]). Boostrix-Polio and Infanrix-IPV [Canadian products] labeling recommend monitoring for hypersensitivity reactions for 30 minutes after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arthus-type hypersensitivity: Patients with a history of severe local reaction (Arthus-type) following a previous diphtheria toxoid or tetanus toxoid containing vaccine dose should not be given further routine or emergency doses of Td more frequently than every 10 years, even if using for wound management with wounds that are not clean or minor; these patients generally have high serum antitoxin levels (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reactions from previous pertussis vaccination: Carefully consider use in patients with history of any of the following effects from previous administration of a pertussis-containing vaccine: Fever &ge;40.5&deg;C (105&deg;F) within 48 hours of unknown cause; seizures with or without fever occurring within 3 days; persistent, inconsolable crying episodes lasting &ge;3 hours and occurring within 48 hours; collapse or shock-like state (hypotonic-hyporesponsive episode) occurring within 48 hours (ACIP [Kroger 2017]). Use is contraindicated in patients who have had encephalopathy within 7 days of a previous pertussis-containing vaccine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Guillain-Barr&eacute; syndrome: Use with caution if Guillain-Barr&eacute; syndrome occurred within 6 weeks of prior tetanus toxoid-containing vaccine (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurologic disorders: Use with caution in patients with progressive neurologic disease including infantile spasms, uncontrolled seizure, or a progressive encephalopathy, or conditions predisposing to seizures. ACIP guidelines recommend deferring immunization until health status can be assessed and condition stabilized (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <i></i>Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP and the NACI recommend simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual components. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand name is unavailable (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adults: Safety and efficacy of Kinrix, Quadracel, and Infanrix IPV [Canadian product] have not been established for use in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014].</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: If Kinrix is inadvertently administered to children for an earlier dose in the series, it may be counted as a valid dose, provided the minimum interval requirements were met (CDC 57[39] 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: Product may contain aluminum.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neomycin: Product may contain neomycin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polymyxin B: Product may contain polymyxin B.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: According to the manufacturer, antipyretics may be considered at the time of and for 24 hours following vaccination to patients at high risk for seizures to reduce the possibility of postvaccination fever. However, antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299216\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215812\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8974&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine: May diminish the therapeutic effect of Tetanus Toxoids Vaccines. Management: When possible, administer the meningococcal polysaccharide (groups A / C / Y and W-135) tetanus toxoid conjugate vaccine either together with or at least one month before a tetanus toxoids-containing vaccine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215691\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215692\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Reproduction studies have not been conducted; Kinrix, Quadracel, and Infanrix-IPV [Canadian product] are not indicated for women of childbearing age. Adacel-Polio [Canadian product] is not recommended for use in pregnant women unless a definite risk of pertussis exists. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215694\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Kinrix, Quadracel, and Infanrix-IPV [Canadian product] are not indicated for use in patients &ge;7 years of age. Use of Adacel-Polio and Boostrix-Polio [Canadian products] in lactating women has not been studied. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13908589\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion. Boostrix-Polio and Infanrix-IPV [Canadian products] labeling recommend monitoring for hypersensitivity reactions for 30 minutes after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215818\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promotes active immunity to diphtheria, tetanus, pertussis, and poliovirus (types 1, 2 and 3) by inducing production of specific antibodies and antitoxins.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6215820\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Immune response observed to all components ~1 month following vaccination</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Immunity against diphtheria, tetanus, and polio persists for 10 or more years after a complete primary immunizing series was given. Periodic tetanus and diphtheria booster doses help maintain specific antitoxin levels above 0.01 antitoxin units/mL for each antigen. More recently, a level of 0.1 to 0.2 units/mL or more has been considered protective. Protection against pertussis from DTaP in children persists approximately 4 to 6 years. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45783204\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Squarekids (JP);</li>\n      <li>Tetraxim (AE, AR, BG, CO, CZ, EE, HK, HU, ID, KR, LB, LT, LV, MY, PH, PL, RO, TH, TR, VN);</li>\n      <li>Tetraxym (RU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adacel-Polio (diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine) [product monograph]. Toronto, Ontario, Canada: Sanofi Pasteur Limited; July 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boostrix-Polio (diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine). [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; March 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Canadian Immunization Guide, Seventh Edition, 2006,&rdquo; Ottawa, ONT: Minister of Public Works and Government Services Canada, Public Health Agency of Canada, National Advisory Committee on Immunization, 2006. Available at http://www.phac-aspc.gc.ca/publicat/cig-gci/index.html</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and Guidance for Use as a Booster Dose,&quot; <i>MMWR Morb Mortal Wkly Rep</i>, 2008, 57(39):1078-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information/abstract-text/18830212 /pubmed\" target=\"_blank\" id=\"18830212 \">18830212 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Routine Poliovirus Vaccination,&rdquo; <i>MMWR Morb Mortal Wkly Rep</i>, 2009, 58(30):829-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information/abstract-text/19661857/pubmed\" target=\"_blank\" id=\"19661857\">19661857</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Infanrix-IPV (diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine). [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kinrix (diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quadracel (diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quadracel (diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine) [product monograph]. Toronto, Ontario, Canada: Sanofi Pasteur Limited; August 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8974 Version 104.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6215528\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14790063\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F6215688\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F14790522\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F6215824\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15796187\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15796188\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6215828\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F6215686\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F14790523\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F46885852\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6215825\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6215690\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14790062\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6215807\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6215695\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6215696\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299216\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6215812\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F6215691\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6215692\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6215694\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13908589\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6215818\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F6215820\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45783204\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8974|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Pediatric drug information</a></li></ul></div></div>","javascript":null}